4//SEC Filing
Shanghai Pharmaceutical (USA) Inc. 4
Accession 0000899243-20-020210
CIK 0001260990other
Filed
Jul 22, 8:00 PM ET
Accepted
Jul 23, 4:32 PM ET
Size
10.3 KB
Accession
0000899243-20-020210
Insider Transaction Report
Form 4
Shanghai Pharmaceutical (USA) Inc.
10% Owner
Transactions
- Purchase
Common Stock
2020-07-21$2.38/sh+1,049,317$2,499,998→ 3,544,431 total(indirect: See footnote) - Purchase
Warrants
2020-07-21$2.38/sh+524,658$1,249,998→ 524,658 total(indirect: See footnote)Exercise: $2.32Exp: 2026-01-21→ Common Stock (524,658 underlying)
Transactions
- Purchase
Common Stock
2020-07-21$2.38/sh+1,049,317$2,499,998→ 3,544,431 total(indirect: See footnote) - Purchase
Warrants
2020-07-21$2.38/sh+524,658$1,249,998→ 524,658 total(indirect: See footnote)Exercise: $2.32Exp: 2026-01-21→ Common Stock (524,658 underlying)
Footnotes (3)
- [F1]Includes (i) 1,049,317 shares held of record by Shanghai Pharmaceuticals (HK) Investment Limited ("SPH HK") and (ii) 2,495,114 shares held of record by Shanghai Pharmaceutical (USA) Inc. ("SPH USA").
- [F2]The shares reported in this transaction are directly held by SPH HK. Each of SPH HK and SPH USA are wholly owned subsidiaries Shanghai Pharmaceuticals Holding Co., Ltd. ("SPH"). As a result, SPH may be deemed to be the beneficial owner of the share held by SPH HK, but disclaims beneficial ownership of all the shares held except to the extent of its pecuniary interest therein.
- [F3]The warrants are currently exercisable into shares of the Issuer's Common Stock except to the extent that the exercise would result in the beneficial ownership of more than 19.99% of the Issuer's outstanding Common Stock.
Documents
Issuer
Oncternal Therapeutics, Inc.
CIK 0001260990
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001778270
Filing Metadata
- Form type
- 4
- Filed
- Jul 22, 8:00 PM ET
- Accepted
- Jul 23, 4:32 PM ET
- Size
- 10.3 KB